Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2022 | Key challenges in developing CAR-T therapy for CLL

Marco Ruella • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, highlights the major obstacles to developing CAR-T for patients with chronic lymphocytic leukemia (CLL), including T cell immune dysfunction, and the highly immunosuppressive microenvironment present in these patients. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Ruella

Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy 12:30
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
Elizabeth Budde et al. • 13 Apr 2025
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis 4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
Do biomarkers exist for predicting response to CAR T-cell therapy? 2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
Resistance to CAR T-cell therapy 2:43
Resistance to CAR T-cell therapy
Marco Ruella • 9 Apr 2024

Related Videos

Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The potential association of plasma venetoclax level with treatment efficacy in first-line AML 2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals